The second installment, of a two-part article on new antiretroviral drugs in development, provides information on five nucleoside and four nonnucleoside reverse transcriptase inhibitors. In addition, two new classes of drugs, fusion inhibitors and integrase inhibitors, are introduced. The results of in vitro and in vivo trials are provided. Researchers hope these new drugs will be more potent, have less cross-resistance, and be better tolerated by HIV-infected patients than current antiretrovirals.
|Original language||English (US)|
|Journal||AIDS clinical care|
|State||Published - Jan 1 1999|
ASJC Scopus subject areas